A recent clinical trial investigated the feasibility and safety of prophylactically administering donor CD8+ T-cells enriched for specificities against peptides from WT-1, PR1, and BCR-ABL to CML patients after T-cell depleted alloSCT[57]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.